Literature DB >> 29992635

Impact of pretransplant recipient body mass index on post heart transplant mortality: A systematic review and meta-analysis.

Farid Foroutan1, Barbara S Doumouras1, Heather Ross1, Ana C Alba1.   

Abstract

The ISHLT's 2016 Guidelines on the selection of heart transplant (HT) candidates recommends weight loss prior to listing for persons with body mass (BMI) index greater than 35 kg/m2 . We conducted a systematic review to assess the impact of BMI on all-cause mortality. We searched to identify eligible observational studies that followed HT recipients. We used the GRADE system to quantify absolute effects and quality of evidence, and meta-analyzed survival curves to assess post-transplant mortality across BMI categories. We found a significantly increased risk of mortality in patients with BMI > 30 kg/m2 across all age categories, independently of transplant era and study source (BMI 30-34.9: HR 1.10, 95% CI 1.04-1.17; BMI ≥ 35: HR 1.24, 95% CI 1.12-1.38). We also found an increased risk of death in underweight (BMI < 18.5 kg/m2 ) candidates over 39 years of age (Age 40-65: HR 1.24, 95% CI 1.02-1.53; Age > 65: HR 1.70, 95% 1.13-2.57). We found obesity and underweight BMI to be associated with mortality post-HT. The similar and overlapping increased risk of mortality in patients with BMI 30-34.9 and BMI ≥ 35 does not support the recently updated ISHLT guidelines. Future evidence in the form of randomized controlled trials is required to assess effectiveness of interventions targeting obesity-related comorbidities and weight management.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  epidemiology; meta-analysis; obesity

Mesh:

Year:  2018        PMID: 29992635     DOI: 10.1111/ctr.13348

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

1.  The effect of recipient BMI on waitlist and post-transplant outcomes after the 2018 heart transplant allocation policy change.

Authors:  Jay N Patel; David G Rabkin; Brett W Sperry; Anju Bhardwaj; Joshua S Chung; Dmitry Abramov
Journal:  J Card Surg       Date:  2022-04-05       Impact factor: 1.778

2.  Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.

Authors:  Carly Adamson; Pardeep S Jhund; Kieran F Docherty; Jan Bělohlávek; Chern-En Chiang; Mirta Diez; Jarosław Drożdż; Andrej Dukát; Jonathan Howlett; Charlotta E A Ljungman; Mark C Petrie; Morten Schou; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Scott D Solomon; Olof Bengtsson; Anna Maria Langkilde; Daniel Lindholm; Mikaela Sjöstrand; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2021-07-29       Impact factor: 17.349

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.